Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01186978 · ClinicalTrials.gov registry record · NA
Reduced Radiation in Patients With Diffuse Large B-cell Lymphoma
A NA study of Diffuse Large B Cell Lymphoma, sponsored by Duke University.
- Completed
- Registry status
- NA
- Development phase
- 63
- Enrollment target
- 3
- Study locations
NCT01186978: Completed NA study of Diffuse Large B Cell Lymphoma, sponsored by Duke University.
NCT01186978 is a NA study of Diffuse Large B Cell Lymphoma that has completed, run by Duke University. The registered enrollment target is 63 participants, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (71% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01186978, a NA study of Diffuse Large B Cell Lymphoma, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- NA
- Development phase
- 63 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study will evaluate whether a reduction in the radiation dose and field size will maintain a high rate of local control while minimizing the risk of acute and late toxicity. Hypothesis- The radiation dose and treatment volume can be safely reduced from 30 Gy to 20 Gy while maintaining high rates of local control in patients who had a negative PET scan following rituximab-containing chemotherapy.
Primary Outcome
This trial will accrue 62 patients over a time period of approximately 5-6 years. The primary objective is to determine whether the number of participants with local control at 5 years, estimated from the Kaplan-Meier curve of time-to-local failure, is as high as that observed in historical controls, i.e., 0.90.
Conditions Studied
Interventions
- RADIATION Radiation Therapy
Study Locations (3)
North Carolina
- Durham Regional Hospital - Durham
- Duke University Medical Center - Durham
- Duke Raleigh Hospital - Raleigh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2010-09-20 |
| Est. Completion | 2019-06-04 |
| Phase | NA |
What the finished NCT01186978 record still lists
NCT01186978 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (71% lower).
The record links to 1 condition, with Diffuse Large B Cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Radiation Therapy is the first listed.
NCT01186978 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT01186978 about?
NCT01186978 is a clinical study titled "Reduced Radiation in Patients With Diffuse Large B-cell Lymphoma". This study will evaluate whether a reduction in the radiation dose and field size will maintain a high rate of local control while minimizing the risk of acute and late toxicity. Hypothesis- The radiation dose and treatment volume can be safely reduced from 30 Gy to 20 Gy while maintaining high rat...
What is the current status of trial NCT01186978?
This trial is currently completed. It is a NA study. The enrollment target is 63 participants. The study started on 2010-09-20. Estimated completion is 2019-06-04.
What conditions does trial NCT01186978 study?
This clinical trial studies the following conditions: Diffuse Large B Cell Lymphoma.
What interventions are being tested in trial NCT01186978?
The interventions under investigation include: Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT01186978?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01186978 being conducted?
This trial has 3 study locations across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diffuse Large B Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01186978's enrollment target sits among peer trials
63 51st of 114 higher than 64 of 114 other Diffuse Large B Cell Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diffuse Large B Cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL
RECRUITING · NA
-
Hyperfractionated Dual Equivalent Fractionated Radiation Therapy
RECRUITING · NA
-
Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma
ACTIVE NOT RECRUITING · NA
-
Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency
ACTIVE NOT RECRUITING · NA
-
Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma
ACTIVE NOT RECRUITING · NA
-
Use of a Patient Preferences Shared Decision-Making Encounter Tool in Clinical Practice for Patients With DLBCL and FL
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI